A Global Comparison of Implementation and Effectiveness of Materiovigilance Program: Overview of Regulations
Overview
Toxicology
Authors
Affiliations
Medical devices, being life-saving tools, are considered to be a boon for healthcare system. However, in addition to their therapeutic effects, there are several ill consequences that are caused by these devices. An effective cohort vigilant system was needed to manage such adverse effects. This had led to the introduction of materiovigilance. Materiovigilance is the study and follow-up of occurrences that arise as a result from the usage of the medical equipment. It not only manages adverse events (AE) but also creates harmonization among countries. Keeping these objectives in focus, the principles, perspectives, and practices with regard to materiovigilance that are followed in the USA, Europe, China, Japan, Australia, Canada, and India are being compared. Such a comparison is essential, which will help us to understand the gaps in the current regulatory systems in the above-mentioned countries and furthermore will provide a comprehensive picture to the regulatory authorities to amend any existing laws if required. These amendments may ensure optimal patient safety by providing them a benign experience from the use of medical devices.
Sojitra B, Patel C, Pandya S, Virani P, Shah P, Patel J Cureus. 2024; 16(7):e64978.
PMID: 39161496 PMC: 11332695. DOI: 10.7759/cureus.64978.
Sapkota B, Palaian S, Shrestha S, Ibrahim M Ther Innov Regul Sci. 2023; 57(4):886-898.
PMID: 37106236 PMC: 10139667. DOI: 10.1007/s43441-023-00514-4.
Biosimilars in Oncology: Latest Trends and Regulatory Status.
Joshi D, Khursheed R, Gupta S, Wadhwa D, Singh T, Sharma S Pharmaceutics. 2022; 14(12).
PMID: 36559215 PMC: 9784530. DOI: 10.3390/pharmaceutics14122721.
Materiovigilance Programme of India: Current status and way forward.
Saifuddin P, Tandon M, Kalaiselvan V, Suroy B, Pattanshetti V, Prakash A Indian J Pharmacol. 2022; 54(3):221-225.
PMID: 35848694 PMC: 9396683. DOI: 10.4103/ijp.ijp_837_21.